Recommendations On Colon Cancer Screening From the 2021 USPTF Guidelines

In this post I link to and excerpt from the Final Recommendation Statemt-Colorectal Cancer: Screening. May 18, 2021, from The U.S. Preventive Services Task Force.

All that follows is from the above.

Recommendation Summary

Population Recommendation Grade
Adults aged 50 to 75 years The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. See the “Practice Considerations” section and Table 1 for details about screening strategies. A
Adults aged 45 to 49 years The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. See the “Practice Considerations” section and Table 1 for details about screening strategies. B
Adults aged 76 to 85 years The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient’s overall health, prior screening history, and preferences. C

 

Clinician Summary

Collapse All

What does the USPSTF recommend? For adults aged 50 to 75 years:
Screen all adults aged 50 to 75 years for colorectal cancer. Grade A
For adults aged 45 to 49 years:
Screen adults aged 45 to 49 years for colorectal cancer. Grade B
For adults aged 76 to 85 years:
Selectively screen adults aged 76 to 85 years for colorectal cancer, considering the patient’s overall health, prior screening history, and patient’s preferences. Grade C
To whom does this recommendation apply? Adults 45 years and older who do not have signs or symptoms of colorectal cancer and who are at average risk for colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).
What’s new? The USPSTF expanded the recommended ages for colorectal cancer screening to 45 to 75 years (previously, it was 50 to 75 years). The USPSTF continues to recommend selectively screening adults aged 76 to 85 years for colorectal cancer.
How to implement this recommendation? Screen all adults aged 45 to 75 years for colorectal cancer. Several recommended screening tests are available. Clinicians and patients may consider a variety of factors in deciding which test may be best for each person. For example, the tests require different frequencies of screening, location of screening (home or office), methods of screening (stool-based or direct visualization), preprocedure bowel preparation, anesthesia or sedation during the test, and follow-up procedures for abnormal findings.Recommended screening strategies include:

  • High-sensitivity guaiac fecal occult blood test (HSgFOBT) or fecal immunochemical test (FIT) every year
  • Stool DNA-FIT every 1 to 3 years
  • Computed tomography colonography every 5 years
  • Flexible sigmoidoscopy every 5 years
  • Flexible sigmoidoscopy every 10 years + annual FIT
  • Colonoscopy screening every 10 years

Selectively screen adults aged 76 to 85 years for colorectal cancer.

Discuss together with patients the decision to screen, taking into consideration the patient’s overall health status (life expectancy, comorbid conditions), prior screening history, and preferences.

What are other relevant USPSTF recommendations? The USPSTF has a recommendation statement on aspirin use to prevent cardiovascular disease and colorectal cancer, available at www.uspreventiveservicestaskforce.org
Where to read the full recommendation statement? Visit the USPSTF website to read the full recommendation statement. This includes more details on the rationale of the recommendation, including benefits and harms; supporting evidence; and recommendations of others.

The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation.

This entry was posted in Cancer Screening, U.S. Preventive Services Task Force. Bookmark the permalink.